In accordance with Article 13 of Law 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 adopted for its implementation as amended and supplemented, the Competition Council makes available to the public the \u201coperation summary\u201d below, containing the information provided by the parties.<\/p>\n
This information was prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not prejudge the Competition Council’s position on the proposed operation.<\/p>\n
The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 adopted for the implementation of Law 104-12 on freedom of prices and competition as amended and supplemented.<\/p>\n
Names of the companies and groups concerned:<\/strong><\/p>\n – The acquirer<\/strong>: The company \u201cHAIYINGKANG (QINGDAO) MEDICAL TECHNOLOGY CO., LTD.\u201d belonging to the group \u201cHAIER GROUP CORPORATION\u201d;<\/p>\n – The target<\/strong>: The company \u201cSHANGHAI RAAS BLOOD PRODUCTS CO., LTD.\u201d.<\/p>\n Nature of the operation<\/strong><\/p>\n – Acquisition of exclusive control.<\/p>\n Economic sectors concerned<\/strong><\/p>\n – Supply of in vitro diagnostic products;<\/p>\n – Supply of blood grouping solutions.<\/p>\n Deadline for interested third parties to submit their observations<\/strong><\/p>\n – 10 days from the date of publication of this press release, i.e. February 12, 2024.<\/p>\n NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES<\/strong><\/p>\n A notification was sent to the Council regarding a concentration operation by which \u201cHaiyingkang (Qingdao) Medical Technology Co., Ltd.\u201d (\u201cHaiyingkang\u201d or the \u201cAcquirer\u201d) intends to acquire exclusive control of \u201cShanghai RAAS Blood Products Co., Ltd.\u201d (\u201cSRAAS\u201d or the \u201cTarget\u201d) by acquiring 20% of all issued and outstanding shares of the Target.<\/p>\n The proposed operation concerns the following companies:<\/p>\n The commercial activities of the companies concerned are as follows:<\/p>\n Done in Rabat on February 1st<\/sup>, 2024.<\/p>\n","protected":false},"excerpt":{"rendered":" In accordance with Article 13 of Law 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 adopted for its implementation as amended and supplemented, the Competition Council makes available to the public the \u201coperation summary\u201d below, containing the information provided by the parties. This information was prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not prejudge the Competition Council’s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 adopted for the implementation of Law 104-12 on freedom of prices and competition as amended and supplemented. Names of the companies and groups concerned: – The acquirer: The company \u201cHAIYINGKANG (QINGDAO) MEDICAL TECHNOLOGY CO., LTD.\u201d belonging to the group \u201cHAIER GROUP CORPORATION\u201d; – The target: The company \u201cSHANGHAI RAAS BLOOD PRODUCTS CO., LTD.\u201d. Nature of the operation – Acquisition of exclusive control. Economic sectors concerned – Supply of in vitro diagnostic products; – Supply of blood grouping solutions. Deadline for interested third parties to submit their observations – 10 days from the date of publication of this press release, i.e. February 12, 2024. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES A notification was sent to the Council regarding a concentration operation by which \u201cHaiyingkang (Qingdao) Medical Technology Co., Ltd.\u201d (\u201cHaiyingkang\u201d or the \u201cAcquirer\u201d) intends to acquire exclusive control of \u201cShanghai RAAS Blood Products Co., Ltd.\u201d (\u201cSRAAS\u201d or the \u201cTarget\u201d) by acquiring 20% of all issued and outstanding shares of the Target. The proposed operation concerns the following companies: Haiyingkang (the Acquirer), 100% owned by \u201cHaier Group Corporation\u201d and exclusively controlled by it; and SRAAS (the Target), a company listed on the Shenzhen Stock Exchange. The commercial activities of the companies concerned are as follows: Regarding Haiyingkang: a vehicle specially established for the needs of the proposed operation. \u201cHaiyingkang\u201d is indirectly wholly owned and exclusively controlled by \u201cHaier Group Corporation,\u201d whose activities are related to the manufacture and distribution primarily of consumer electronics and household appliances worldwide; and Regarding SRAAS: the manufacture of blood products in China, which includes plasma collection, research and development, production, and sale of blood products. Done in Rabat on February 1st, 2024.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[],"class_list":["post-41609","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"acf":[],"yoast_head":"\n\n
\n